Association of delayed chemoradiotherapy with elevated Epstein-Barr virus DNA load and adverse clinical outcome in nasopharyngeal carcinoma treatment during the COVID-19 pandemic: a retrospective study

• Published in: Cancer cell international Vol. 22; no. 1; pp. 1 - 8
• Main Authors: Huang, Cheng-Long, Fang, Xue-Liang, Mao, Yan-Ping, Guo, Rui, Li, Wen-Fei, Xu, Si-Si, Ma, Jun, Chen, Lei, Tang, Ling-Long
• Format: Journal Article
• Language: English
• Published: London BioMed Central 31.10.2022; BMC
• Subjects: Cancer therapies; Chemoradiotherapy; Chemotherapy; Clinical outcomes; Coronaviruses; COVID-19; COVID-19 pandemic; Deoxyribonucleic acid; Disease transmission; DNA; DNA viruses; EBV DNA; Epstein-Barr virus; Medical prognosis; Metastasis; Nasopharyngeal carcinoma; Pandemics; Patients; Radiation therapy; Severe acute respiratory syndrome coronavirus 2; Throat cancer; Tomography; Treatment delay; China
• DOI: 10.1186/s12935-022-02748-y
• ISSN: 1475-2867

Background: To summarize the impact of radiotherapy (RT) and chemotherapy delays on patients with nasopharyngeal carcinoma (NPC) during the COVID-19 pandemic. Methods: We retrospectively included 233 patients with stage II-IVa NPC treated with RT and chemotherapy between December 11, 2019 and March 11, 2020. The outcomes were elevation in the EBV DNA load between two adjacent cycles of chemotherapy or during RT, and 1-year disease-free survival (DFS). Results: RT delay occurred in 117 (50%) patients, and chemotherapy delay occurred in 220 (94%) patients. RT delay of ≥ 6 days was associated with a higher EBV DNA elevation rate (20.4% vs. 3.6%, odds ratio [OR] = 6.93 [95% CI = 2.49–19.32], P < 0.001), and worse 1-year DFS (91.2% vs. 97.8%, HR = 3.61 [95% CI = 1.37–9.50], P = 0.006), compared with on-schedule RT or delay of < 6 days. Chemotherapy delay of ≥ 10 days was not associated with a higher EBV DNA elevation rate (12.5% vs. 6.8%, OR = 1.94 [95% CI = 0.70–5.40], P = 0.20), or worse 1-year DFS (93.8% vs. 97.1%, HR = 3.73 [95% CI = 0.86–16.14], P = 0.059), compared with delay of < 10 days. Multivariable analyses showed RT delay of ≥ 6 days remained an independent adverse factor for both EBV DNA elevation and DFS. Conclusion: To ensure treatment efficacy for patients with nonmetastatic NPC, initiation of RT should not be delayed by more than 6 days; the effect of chemotherapy delay requires further investigation.